DFTX

Definium Therapeutics

• Simply Wall St·1d ago

  A Look At Definium Therapeutics (DFTX) Valuation After DT120 Advances Through Multiple Phase III Trials

• Seeking Alpha·3d ago

  Definium Therapeutics: High-Stakes Data Readouts Poised To Validate Best-In-Class Potential

• TipRanks·3d ago

  Jefferies Reaffirms Their Buy Rating on Definium Therapeutics (DFTX)

• PUBT·3d ago

  Definium Therapeutics to join Jefferies Global Healthcare Conference fireside chat

• Simply Wall St·3d ago

  Does Definium Therapeutics' (DFTX) New Phase 3 Trial Clarify Its Psychedelic Depression Strategy Or Cloud It?

• TipRanks·4d ago

  Definium Therapeutics Nears Pivotal Earnings Call Tests

• TipRanks·5d ago

  Definium Highlights Late-Stage Psychedelic-Inspired Psychiatric Pipeline

• Reuters·6d ago

  Trump's psychedelic drug order boosts investor interest with promise of faster reviews

• TipRanks·05/16 14:35

  LifeSci Capital Remains a Buy on Definium Therapeutics (DFTX)

• TipRanks·05/14 18:50

  Psychedelic: Compass Pathways, AtaiBeckley, GH Research report earnings

• Simply Wall St·05/14 05:28

  Definium Therapeutics (DFTX) Is Down 6.0% After Starting Second Phase 3 DT120 Trial in MDD - Has The Bull Case Changed?

• TipRanks·05/13 10:35

  Definium Therapeutics: Buy Rating Reiterated with Unchanged $70 Price Target on Robust Late-Stage DT120 Pipeline and De-Risked Phase 3 Programs

• TipRanks·05/13 10:25

  Analyst Reiterates Buy on Definium Therapeutics as Late-Stage MDD and GAD Trials Advance; $38 Price Target Maintained

• TipRanks·05/12 16:50

  Analysts Offer Insights on Healthcare Companies: Definium Therapeutics (DFTX) and Sagimet Biosciences, Inc. Class A (SGMT)

• TipRanks·05/12 13:33

  Definium begins second Phase 3 trial for DT120